Bapineuzumab for mild to moderate Alzheimer’s disease in two global, randomized, phase 3 trials

BACKGROUND: Our objective was to evaluate the efficacy (clinical and biomarker) and safety of intravenous bapineuzumab in patients with mild to moderate Alzheimer’s disease (AD). METHODS: Two of four phase 3, multicenter, randomized, double-blind, placebo-controlled, 18-month trials were conducted g...

Descripción completa

Detalles Bibliográficos
Autores principales: Vandenberghe, Rik, Rinne, Juha O., Boada, Mercè, Katayama, Sadao, Scheltens, Philip, Vellas, Bruno, Tuchman, Michael, Gass, Achim, Fiebach, Jochen B., Hill, Derek, Lobello, Kasia, Li, David, McRae, Tom, Lucas, Prisca, Evans, Iona, Booth, Kevin, Luscan, Gerald, Wyman, Bradley T., Hua, Lisa, Yang, Lingfeng, Brashear, H. Robert, Black, Ronald S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4866415/
https://www.ncbi.nlm.nih.gov/pubmed/27176461
http://dx.doi.org/10.1186/s13195-016-0189-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4866415/
https://www.ncbi.nlm.nih.gov/pubmed/27176461
http://dx.doi.org/10.1186/s13195-016-0189-7

Ejemplares similares